Edward Gabrielson
Overview
Explore the profile of Edward Gabrielson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
131
Citations
8866
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Debeljak M, Cho S, Downs B, Considine M, Avin-McKelvey B, Wang Y, et al.
Breast Cancer Res
. 2024 Dec;
26(1):178.
PMID: 39633428
Background: Ductal carcinoma in-situ (DCIS) is a pre-invasive form of invasive breast cancer (IBC). Due to improved breast cancer screening, it now accounts for ~ 25% of all breast cancers....
2.
Deutsch J, Wang D, Chen K, Cimino-Mathews A, Thompson E, Jedrych J, et al.
Lab Invest
. 2024 Oct;
105(1):102166.
PMID: 39461426
Pathologic response is an endpoint in many ongoing clinical trials for neoadjuvant regimens, including immune checkpoint blockade and chemotherapy. Whole-slide scanning of glass slides generates high-resolution digital images and allows...
3.
Deutsch J, Cimino-Mathews A, Thompson E, Provencio M, Forde P, Spicer J, et al.
Nat Med
. 2023 Oct;
30(1):218-228.
PMID: 37903504
Neoadjuvant immunotherapy plus chemotherapy improves event-free survival (EFS) and pathologic complete response (0% residual viable tumor (RVT) in primary tumor (PT) and lymph nodes (LNs)), and is approved for treatment...
4.
Gabrielson K, Myers S, Yi J, Gabrielson E, Jimenez I
Comp Med
. 2023 Oct;
73(5):407.
PMID: 37788893
This corrects the article DOI: 10.30802/AALAS-CM-22-000095. In the original article entitled "Comparison of Cardiovascular Pathology in Animal Models of SARS-CoV-2 Infection: Recommendations Regarding Standardization of Research Methods," published in Vol...
5.
Gabrielson K, Myers S, Yi J, Gabrielson E, Jimenez I
Comp Med
. 2023 Feb;
73(1):58-71.
PMID: 36731878
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged as the viral pathogen that led to the global COVID-19 pandemic that began in late 2019. Because SARS-CoV-2 primarily causes a respiratory...
6.
Mishra A, Kumar D, Gupta K, Lofland G, Sharma A, Banka D, et al.
Clin Cancer Res
. 2022 Nov;
29(3):581-591.
PMID: 36449662
Purpose: Immune checkpoint therapy (ICT) is currently ineffective in a majority of patients. Tumor drug exposure measurements can provide vital insights into mechanisms involved in the resistance of solid tumors...
7.
Hong J, Shen Y, Hsu C, Huang P, Tomaszewski A, Gabrielson E, et al.
Genes Dis
. 2022 Sep;
9(6):1408-1411.
PMID: 36157486
No abstract available.
8.
Huang P, Illei P, Franklin W, Wu P, Forde P, Ashrafinia S, et al.
Cancers (Basel)
. 2022 Sep;
14(17).
PMID: 36077686
Background: Prognostic risk factors for completely resected stage IA non-small-cell lung cancers (NSCLCs) have advanced minimally over recent decades. Although several biomarkers have been found to be associated with cancer...
9.
Seo S, Woo S, Im S, Jang Y, Han E, Kim S, et al.
Cell Death Dis
. 2022 Feb;
13(2):115.
PMID: 35121737
Cathepsin D (Cat D) is well known for its roles in metastasis, angiogenesis, proliferation, and carcinogenesis in cancer. Despite Cat D being a promising target in cancer cells, effects and...
10.
Tully E, Bharti S, Woo J, Bhujwalla Z, Gabrielson E
Cancer Biol Ther
. 2021 Nov;
22(10-12):579-586.
PMID: 34720054
Biguanide drugs (metformin and phenformin) have drawn interest for potential cancer treatments, and laboratory studies show that some cancer cells are selectively sensitive to growth-inhibitory effects of biguanides. Examining metabolic...